{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:45:21Z","timestamp":1777934721453,"version":"3.51.4"},"reference-count":16,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Establishing benchmarks for extravasation incidences with systemic anti-cancer therapy from various global regions is crucial. Reliable data can inform practices aimed at reducing both the occurrence and severity of extravasation events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective observational study evaluated extravasation incidences in patients receiving systemic anti-cancer therapy for solid tumors at a tertiary oncology daycare center over a period of 15 months. Multiple risk factors potentially contributing to extravasation and influencing its severity were systematically recorded and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 66,540 infusions, a total of 58 extravasation cases were identified, resulting in an overall incidence of 0.087%. The extravasation incidence was 0.13% for vesicant drugs and 0.045% for irritant drugs. Specifically, DNA-binding vesicants had an incidence of 0.2%, while non-DNA binding vesicants had an incidence of 0.11%. The predominant symptom reported was infusion site swelling (86%), followed by pain (43%) and erythema (36%). Grade 3 extravasation occurred in 13 cases (22.4%), with vesicants responsible for all but one event. Median symptom resolution time was 20 days overall, extending to 40 days in grade 3 cases. Notably, the occurrence of symptoms either during infusion or within 6\u2005h post-infusion significantly correlated with milder grade 1 extravasations, lower incidence of severe grade 3 cases, and quicker symptom resolution within three weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Daycare oncology centers should implement standardized protocols for systemic therapy administration, emphasizing preventive strategies and prompt identification and management of extravasation to reduce associated morbidity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251372872","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T14:49:11Z","timestamp":1760626151000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Extravasation with systemic anti-cancer directed therapy administration at daycare in a tertiary care oncology centre: Insights from a prospective observational study (EXACT study)"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7656-8650","authenticated-orcid":false,"given":"Bipinesh","family":"Sansar","sequence":"first","affiliation":[{"name":"Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre"},{"name":"Homi Bhabha National Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6006-2631","authenticated-orcid":false,"given":"Akhil","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre"},{"name":"Homi Bhabha National Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj","family":"Gupta","sequence":"additional","affiliation":[{"name":"Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre"},{"name":"Homi Bhabha National Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bal Krishna","family":"Mishra","sequence":"additional","affiliation":[{"name":"Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre"},{"name":"Homi Bhabha National Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpita","family":"Singh","sequence":"additional","affiliation":[{"name":"Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre"},{"name":"Homi Bhabha National Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamalkant","family":"Ojha","sequence":"additional","affiliation":[{"name":"Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre"},{"name":"Homi Bhabha National Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajasekhar","family":"Dandeti","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute"},{"name":"Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh214"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1188\/21.CJON.680-686"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v7.i1.87"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh049"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103932"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.15761\/HMO.1000196"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e32835cfef1"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds294"},{"key":"e_1_3_2_10_2","first-page":"81","article-title":"Chemotherapy-induced extravasation injury: classification and management","volume":"2","author":"Hassan DS","year":"2022","unstructured":"Hassan DS, Hasary HJ. Chemotherapy-induced extravasation injury: classification and management. Al-Rafidain J Med Sci (ISSN 2789-3219) 2022; 2: 81\u201392.","journal-title":"Al-Rafidain J Med Sci (ISSN 2789-3219)"},{"key":"e_1_3_2_11_2","first-page":"438","article-title":"Chemotherapy extravasation: establishing a national benchmark for incidence among cancer centers","volume":"21","author":"Jackson-Rose J","year":"2017","unstructured":"Jackson-Rose J, Del Monte J, Groman A, et al. Chemotherapy extravasation: establishing a national benchmark for incidence among cancer centers. Clin J Oncol Nurs 2017; 21: 438\u2013445.","journal-title":"Clin J Oncol Nurs"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt186"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2022.1460"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkae054"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1761440"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-97923-2"},{"key":"e_1_3_2_17_2","article-title":"Triple oral metronomic chemotherapy versus chemotherapy of physician discretion after failure of platinum-based therapy in advanced head and neck cancer: a phase iii randomized study (METRO-CHASE study)","volume":"11","author":"Kapoor A","year":"2025","unstructured":"Kapoor A, Gupta A, Sansar B, et al. Triple oral metronomic chemotherapy versus chemotherapy of physician discretion after failure of platinum-based therapy in advanced head and neck cancer: a phase iii randomized study (METRO-CHASE study). JCO Glob Oncol 2025; 11: e2500032.","journal-title":"JCO Glob Oncol"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251372872","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251372872","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251372872","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:31:40Z","timestamp":1777689100000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251372872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":16,"alternative-id":["10.1177\/10781552251372872"],"URL":"https:\/\/doi.org\/10.1177\/10781552251372872","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"article-number":"10781552251372872"}}